Karagiannis Panagiotis, Gilbert Amy E, Nestle Frank O, Karagiannis Sophia N
Cutaneous Medicine and Immunotherapy Unit; St. John's Institute of Dermatology; Division of Genetics and Molecular Medicine & NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London; London, UK.
Oncoimmunology. 2013 Jul 1;2(7):e24889. doi: 10.4161/onci.24889. Epub 2013 May 7.
The role of B cells and antibodies in cancer is insufficiently understood but is receiving increasing attention. We have recently identified IgG4 as an antibody subclass elicited by melanoma-associated interleukin-10-driven inflammation. In this setting, IgG4 exhibit inefficient immunostimulatory capacity and block the cytotoxic activities of other antibodies. These previously unappreciated mechanisms of immune escape may constitute promising targets for the development of novel anticancer immunotherapies.
B细胞和抗体在癌症中的作用尚未得到充分了解，但正受到越来越多的关注。我们最近发现IgG4是由黑色素瘤相关的白细胞介素-10驱动的炎症引发的抗体亚类。在这种情况下，IgG4表现出低效的免疫刺激能力，并阻断其他抗体的细胞毒性活性。这些以前未被认识的免疫逃逸机制可能构成开发新型抗癌免疫疗法的有希望的靶点。
